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Nontuberculous mycobacterial (NTM) lung disease is a signifi cant cause of morbidity and mortality among individuals with preexisting lung conditions such as bronchiectasis and COPD. 1, 2 Mycobacterium avium complex (MAC) and Mycobacterium abscessus (Mab) are the most common NTM respiratory pathogens in the United States. Treatment outcomes for noncavitary MAC lung disease have been generally favorable with macrolide-containing regimens. [3] [4] [5] Unfortunately, there are no predictable or reliably eff ective treatment strategies for lung disease caused by Mab with a functional erythromycin resistance methlyase gene ( erm ). 6 MAC and Mab lung diseases are similar to multidrug-resistant TB (MDR-TB) in that there are relatively few treatment options available, especially for patients who fail "standard" therapy. New drug therapies for MAC and macrolideresistant Mab lung diseases are urgently needed.
Bedaquiline (Sirturo, TMC 207) was approved for treatment of MDR-TB by the Food and Drug Administration in December 2012 ( e-Appendix 1 ). Bedaquiline is a diarylquinoline antibiotic that acts through a novel antimicrobial mechanism by inhibiting ATP synthase, an enzyme essential to generate energy for TB. 7 Th e US Food and Drug Administration approval of bedaquiline was based on two phase 2 studies involving 440 individuals with MDR-TB. 8, 9 Bedaquiline, when given with other MDR-TB drugs, increased sputum conversion rates in the short term and reduced the amount of time to sputum conversion compared with non-bedaquilinecontaining regimens. Th e approval of bedaquiline was also accompanied by controversy because in one study there was posttreatment excess mortality in the patient group receiving bedaquiline.
Bedaquiline has been shown to have bacteriostatic activity against MAC and Mab but with lower minimal inhibitory concentrations for MAC than for Mycobacterium tuberculosis (MTB); there are comparable minimal inhibitory concentrations for Mab in in vitro and mouse models. 10, 11 Although bedaquiline has impressive in vitro activity for NTM, the clinical activity of the drug among individuals with NTM lung disease has not been studied. We describe the treatment with bedaquiline-containing regimens of individuals with refractory Mab or MAC lung disease who remained acid-fast bacilli (AFB) culture positive despite aggressive guidelines-directed therapy. 6 
Materials and Methods
Patients with MAC and Mab lung disease treated at the University of Texas Health Science Center at Tyler (UTHSCT), Tyler, Texas, are included in this report. Th is was a retrospective analysis of prospectively collected data as approved by the institutional review board of UTHSCT (IRB No. 957).
Patients were included in this study if they were Ն 18 years of age, met the criteria for NTM lung disease as defined by the American Thoracic Society/Infectious Disease Society of America guidelines, and failed Ն 12 months of therapy for MAC and Ն 6 months for Mab. 6 Treatment failure was defined as persistent positive sputum cultures for NTM, with progressive symptoms and radiographic abnormalities. All were considered to have potentially life-threatening NTM disease. Bedaquiline was not available through the manufacturer for clinical trial purposes; therefore, only patients with approved commercial insurance or copay assistance were included in this study.
Th e necessity of obtaining the drug from a single pharmacy and the universal need for insurance reimbursement to obtain the drug precluded a blinded or randomized trial. All patients identifi ed as possible candidates for bedaquiline were given information describing the drug and previously reported adverse events ( e-Appendix 1 ). Specifi cally, the excess mortality seen with bedaquiline in the MDR-TB studies was discussed in detail. 12 Patients were given the same information about the excess bedaquiline-associated mortality that was provided to physicians by the Centers for Disease Control and Prevention. 13, 14 Patients were excluded from this study if they had a history of Torsade de Pointes; congenital long QT syndrome; a history of untreated hypothyroidism and bradyarrhythmia; uncompensated heart failure; serum calcium, magnesium, or potassium levels below the lower limits of normal; or HIV seropositivity; if they were pregnant or of childbearing age and not on adequate birth control; or if they had a history of alcohol abuse or active hepatitis B or C or other advanced liver disorders. We also assessed the short-term prognosis of each patient. With the exception of one patient early in the investigation who was approved for bedaquiline but did not receive it (see further discussion), patients perceived to have , 12 months anticipated survival were excluded.
Patients with macrolide-susceptible MAC were treated with azithromycin, 500 mg given three times weekly (TIW) ; ethambutol, 25 mg/kg given TIW; IM or IV streptomycin dosed at 7 mg/kg given TIW; or amikacin given IV at 7 mg/kg TIW. Th e macrolide was omitted if the MAC isolate was macrolide resistant. If the patient had macrolideresistant MAC, rifabutin, 150 to 300 mg TIW, was used. 15 Doses for both aminoglycosides were titrated to achieve a peak level of 20 to 25 m g/mL. If the patient could not tolerate IM or IV aminoglycoside therapy, the injectable drug was stopped, and inhaled amikacin, 500 mg daily or TIW via a Pari LC nebulizer (PARI International), was used in combination with oral drugs. 16 Rifampin was omitted in almost all patients because of its signifi cant induction of the hepatic metabolism of bedaquiline. 17 Bedaquiline was dosed at 400 mg (four tablets of 100 mg) po once daily with food for the first 2 weeks. The dose was then decreased to 200 mg (two tablets of 100 mg) TIW with food for a total of 600 mg per week.
Patients with amikacin-susceptible Mab were treated with IV amikacin, 7 mg/kg given at least fi ve times weekly. Doses were titrated to achieve a peak level of 20 to 25 m g/mL. IV cefoxitin, up to 6 to 8 g daily in divided doses, imipenem, 500 to 1,000 mg bid, or tigecycline, 25 to 50 mg daily, and/or linezolid, 300 to 600 mg po daily, were given, depending on susceptibility patterns. Amikacin was omitted if the Mab isolate was resistant. 18 Bedaquiline was dosed as in the MAC protocol. If the isolate for Mab had a nonfunctional erm gene and in vitro susceptibility to macrolide/azalide, azithromycin was given at doses of 250 to 500 mg po daily. [19] [20] [21] For both species, drug regimens were given for a minimum of 24 weeks. Pretreatment chest radiograph and high-resolution CT scan, sputum for AFB smear and culture, CBC count, complete metabolic panel, serum magnesium and phosphorous levels, and ECG were obtained. An ECG, complete metabolic panel, CBC count, serum magnesium and phosphorous levels, and peak streptomycin or amikacin levels were obtained at 2 weeks and then every month while on bedaquiline. Patients were evaluated in clinic at least once per month while on therapy with drugs being distributed, and side eff ects were assessed at that time ( e-Appendix 1 ). Sputum for AFB smear and culture was obtained at baseline and at least monthly, either by clinic visit or via mail.
Sputum samples were processed in the UTHSCT clinical laboratory using standard decontamination procedures, fl uorochrome microscopy, solid media culture on a biplate of Middlebrook 7H10 agar with and without antibiotics, and a broth culture (ESP; Th ermo Fisher Scientifi c, formerly TREK Diagnostic Systems) as described previously. 6, 22 MAC isolates were identified using AccuProbe (Hologic Gen-Probe). Mab isolates were identifi ed to species and subspecies using sequencing of region 5 of the rpo b gene and polymerase chain reaction restriction fragment length analysis of an approximately 441 base pairs heat shock protein gene ( hsp ) 23 using two restriction endonucleases, BstE II and Hae III, as described previously. 24, 25 A third restriction enzyme, Sml I, was added to diff erentiate Mab subspecies massiliense from Mab subspecies bolletii . Semiquantitative AFB smear and culture results for each submitted clinical specimen during and aft er therapy were recorded as described previously ( Table 1 ) . 6, 22 Macrolide/azalide susceptibilities for MAC used broth microdilution according to contemporary guidelines. 19 Clarithromycin was used as the class drug for both macrolide and azalide susceptibility. We were not able to perform in vitro susceptibility studies for beda quiline on our clinical NTM isolates because the drug was not available. Routine radiographs, chest radiographs, and CT scans were performed at baseline. Chest radiographs were performed monthly and CT scans at the discretion of the provider. Baseline CT scans were compared with CT scans performed aft er 6 months of bedaquiline therapy and were read independently by two radiologists.
Results
We identifi ed 17 patients between July and December 2013 who were deemed eligible for bedaquiline therapy. Six of the 17 patients (35%) were excluded because their insurance would not pay any part of the cost for bedaquiline ( Table 2 ) . No patient without insurance coverage opted to pay for the medication out of pocket. Eleven of the 17 patients (65%) were able to obtain bedaquiline via commercial insurance. One patient died prior to starting bedaquiline therapy because of advanced MAC lung disease. Ten patients described in this report completed Ն 6 months of therapy. Two of these patients had cystic fi brosis.
Nine of 10 patients (90%) had symptomatic improvement as defi ned by less cough, less sputum production, improved energy level, and/or weight stabilization or gain at 2 months of therapy ( Table 3 ) . Forty percent (four of 10) had radiographic improvement at 6 months of therapy. Twenty percent (two of 10) were deemed stable or unchanged, and 40% (four of 10) suggested worsening. Of the four patients whose CT scan appeared worse, two patients with bronchiectasis but not cystic fi brosis had intercurrent pneumonia while receiving bedaquiline therapy, requiring additional antibacterial antibiotic therapy, and two patients had cystic fi brosis exacerbations while taking bedaquiline, requiring additional antibacterial therapy. Sixty percent (six of 10) had an improvement in semiquantitative sputum culture scores at 6 months, with 50% (fi ve of 10) having one or more negative cultures ( Table 1 ) .
Twenty percent (two of 10) had no identifi able improvement in semiquantitative sputum scores but did not exhibit increased symptoms. Sixty percent (six of 10) had GI side eff ects, specifi cally nausea, which was felt to be related to bedaquiline ( Table 4 ) . Th ere were no cardiac-related adverse events, signifi cantly prolonged corrected QT (QTc) interval, or signifi cant changes in biochemistry panels. Th e average change in the QTc interval by 12-lead ECG testing was 4.6 ms at 1 month, 6.5 ms at 3 months, and 2.4 ms at 6 months. No patients stopped the drug because of adverse events.
Baseline (at the
Start of Therapy) 1 mo 2 mo 3 mo 4 mo 5 mo 6 mo 1 Mab 4 1 3 1 1 1 2 1 3 1 1 1 2 1 2 Mab 1 1 3 1 1 1 35 colonies 37 colonies 16 colonies 3 1 3 Mab 4 1 28 colonies Negative 8 colonies Negative Negative 32 colonies 4 Mab 4 1 4 1 4 1 4 1 4 1 4 1 4 1 5 MAC 4 1 3 1 4 1 4 1 4 1 4 1 4 1 6 MAC 4 1 4 1 Negative Negative 2 1 4 1 3 1 7 MAC 4 1 4 1 30 colonies Negative Negative … a … a 8 MAC 4 1 1 1 Negative 3 1 4 1 4 1 4 1 9 MAC 4 1 2 1 3 1 1 colony 4 colonies 1 1 4
Discussion
In this evaluation of patients with refractory MAC and Mab lung disease, we found a modest favorable clinical response aft er 6 months of therapy with a bedaquilinecontaining treatment regimen. Most patients had improved sputum AFB culture results. No patient had sustained sputum conversion to AFB culture negative. Bedaquiline was generally well tolerated, the most common side eff ect being nausea, which occurred primarily during the initial 2 weeks of high-dose bedaquiline therapy. We found no evidence of cardiac toxicity, specifi cally no clinically signifi cant QTc interval prolongation.
Although not comparable to the more dramatic results with drug-resistant TB, the microbiologic results of bedaquiline in this small cohort of patients with NTM lung disease are still promising. A major diff erence between MTB and NTM is that bedaquiline is bactericidal for MTB but not for MAC or Mab. A diff erence in treatment response for MAC and MTB in a murine model was assumed to be attributable, in part, to the diff erence in killing activity of the two species. 11 Another factor is that virtually all patients had been on the complimentary drugs for prolonged periods of time with minimal or no response. A fi nal factor is the possible development of bedaquiline resistance before any clinical or microbiologic benefi t could be measured.
Th ere have been and continue to be concerns about the safety of bedaquiline for the treatment of mycobacterial diseases because of the excess mortality found in a bedaquiline treatment arm for MDR-TB. 12 Th ese deaths have been analyzed in detail and to date, there is not a clear connection between, or a known mechanism for, the deaths and the administration of bedaquiline itself. One concern about bedaquiline has been QTc interval prolongation and the risk of sudden death. We found no signifi cant QTc interval prolongation. All patients in this study will continue to undergo follow-up for Ն 24 months aft er discontinuation of the bedaquiline.
Based on the in vitro data showing activity of bedaquiline against NTM, it was inevitable that there would be interest in the use of bedaquiline for patients with NTM lung disease. We elected to pursue bedaquiline for selected patients for several reasons. As noted, treatmentrefractory MAC and Mab lung disease is statistically less likely than MDR-TB to respond to medical therapy. Th ere are fewer drugs currently available for the treatment of MAC and Mab than for MDR-TB. Symptoms were compared monthly with symptoms prior to bedaquiline therapy. Aside from inhaled liposomal amikacin, there are no drugs currently in development for MAC or Mab lung disease. 26 From a safety perspective, the cornerstone of treatment of MAC and Mab are clarithromycin or azithromycin, both known to prolong the QTc interval, and both implicated in excess mortality aft er shortcourse treatment (days). [27] [28] [29] Unfortunately, there is no established animal model for NTM lung disease, so we are left to rely on human treatment trials. Admittedly, this report does not defi nitively answer the risk/benefi t questions about bedaquiline therapy for NTM lung disease. However, we have shown short-term safety of the drug and modest therapeutic success, both of which should support future studies.
Th is report has several limitations. First, we studied bedaquiline in patients with NTM lung disease who had been treated with multiple antibiotics over long time periods without success. Th is group of patients is notoriously diffi cult to treat eff ectively. Th is is an observational evaluation based on a very small cohort of patients. Th e report was limited by our ability to obtain the drug only for patients with insurance coverage. We reported outcome characteristics and side eff ects at 6 months of therapy, and the duration of patient exposure to bedaquiline could have been insuffi cient to detect a more favorable response. Although many patients had symptomatic improvement attributed to bedaquiline, this result could have been complicated by the aggressive overall regimen, including an aminoglycoside. We were not able to perform in vitro susceptibility studies for bedaquiline on our clinical NTM isolates, and the possibility of the development of bedaquiline resistance remains.
A variety of in vitro-acquired resistant mechanisms are reported in MTB. 30, 31 Milano et al 30 report that azole resistance in MTB is mediated by the MmpS5-MmpL5 effl ux system, a mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. 30 The mechanisms of bedaquiline resistance in Mab and MAC have not been determined. To avoid in vitro-acquired bedaquiline resistance, we chose as many potentially eff ective companion agents as possible to be given with bedaquiline. Despite this precaution, it is possible that patient isolates in this series acquired bedaquiline resistance, especially cases 6 and 8, who converted their sputum and then became heavily positive again ( Table 1 ).
All six patients with MAC also received a rifamycin (rifabutin), which is known to decrease bedaquiline levels. Rifamycins also decrease macrolide levels, which have not been shown to adversely aff ect MAC treatment outcome. Additionally, it is not known if TIW bedaquiline dosing is sufficient for Mab, which is treated daily with other antimicrobials. Another major limitation that makes this a preliminary study is that the serious adverse events (deaths) noted in the MTB trials in bedaquiline occurred a mean of 12 months aft er stopping the drug.
Conclusions
Th ere are limited treatment options for treatmentrefractory NTM cases or for those with resistant NTM isolates. IV antibiotics are an essential element for aggressive MAC lung disease treatment and a necessity for Mab lung disease treatment. Unfortunately, oral and parenteral medication options are limited in both settings. Further study is clearly required to determine whether bedaquiline has a place in the management of NTM lung disease, and if so, to guide its appropriate use.
